checkAd

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO

Nachrichtenquelle: globenewswire
10.04.2021, 19:31  |  173   |   |   

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer

DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers

Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States

KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT

IRVINE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, presented new data at the American Association for Cancer Research (AACR) Annual Meeting 2021, being held virtually from April 10-15, 2021. The presentations featured studies of Oncocyte’s novel predictor of immunotherapy response, DetermaIO, demonstrating test performance in bladder cancer, now the third cancer type, suggesting potential applicability across multiple cancer types. DetermaIO has previously been shown to predict immunotherapy response in lung and breast cancers in studies using four different approved checkpoint inhibitors – Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab) and Imfinzi (durvalumab).

At the conference, Oncocyte debuted data in bladder cancer in two studies, including one highlighted in a podium presentation. The poster, titled “Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer,” detailed the application of the DetermaIO test and proprietary algorithm for the classification of metastatic bladder cancer. This study demonstrated a novel approach of looking at the tumor microenvironment (TME) at a genomic scale, as well as validating the use of the test, without any further modification, in bladder cancer to assess its association with Immune Checkpoint Inhibitor (ICI) response. A link to poster can be found here and accompanying explanation can be found here.

During the podium presentation, titled “Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor,” Robert Seitz, Head of Immune Oncology at Oncocyte and lead author of the study, revealed the results of a prospectively defined analysis of clinical trial results from the IMvigor210 study of atezolizumab (TECENTRIQ), an immunotherapy used to treat bladder and other cancers. A replay of the presentation can be accessed here.

Seite 1 von 6
OncoCyte Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel